© 2019, Dokkyo University School of Medicine. All rights reserved. Multiple large-scale clinical trials have indicated that sodium glucose cotransporter 2 (SGLT2) inhibitors reduce the incidence of cardiovascular events, deterioration of renal function and mortality. However, the therapeutic effects of SGLT2 inhibitors are supposed to be limited in patients with reduced renal function considering the mechanism of their action. In this study, a SGLT2 inhibitor, ipragliflozin was given to 30 type 2 diabetic patients with nephropathy whose estimated glomerular filtration rate (eGFR) was not lower than 30 mL/min/1.73 m2. After 12 to 16 weeks, hemoglobin A1c decreased by 0.6％ (p＜0.001), body weight was reduced by 1.8 kg (p＜0.01) and blood pressure was lowered by －10/－6 mmHg (p＜0.001/p ＜0.001).. This was accompanied by reductions in serum uric acid (－0.7 mg/dL, p＜0.001), triglycerides (－25 mg/dL, p＝0.028) and g-glutamyl transferase (－8 U/L, p＝0.001). On the other hand, plasma B-type natriuretic peptide also decreased by 12％ (p＝0.020) and urinary albumin excretion was reduced by 23％ (p＝0.018) although the eGFR was not significantly changed. It is concluded that ipragliflozin is effective in lowering blood glucose even in patients with diabetic kidney disease and is beneficial in improving the accompanying obesity and hypertension. In addition, ipragliflozin is thought to have favorable influences on the metabolisms of uric acid and lipids. These properties of ipragliflozin is expected to bring about protective effects against the progression of nephropathy and the development of cardiovascular disease resulting in the improvement of prognosis in diabetic patients with mild to moderate chronic kidney disease.